Videos

Thomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).

Sharyn N. Lewin, MD, discusses the importance of screening patients with ovarian cancer for a BRCA mutation.

Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).

Deanna J. Attai, MD, discusses the future of surgery and targeted therapies in the treatment of breast cancer.

Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the impact on quality of life of dermatologic adverse events.

Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).

Omid Hamid, MD, discusses sequencing and combining targeted therapies in the treatment of melanoma.

Jason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, comments on the development of biomarkers for lung cancer.

Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.

Prudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.

Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.

Donna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.

Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.

Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.

Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

Adam Bass, MD, assistant professor, Harvard Medical School, Dana-Farber Cancer Institute, provides an overview of the four subtypes of gastric cancer identified in a recent study.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses the benefits and challenges associated with stool DNA test for colon cancer.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.

Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.